Share Price and Basic Stock Data
Last Updated: December 16, 2025, 5:00 pm
| PEG Ratio | 3.54 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sharda Cropchem Ltd operates in the agrochemicals sector, providing a range of products including pesticides and other crop protection solutions. The company’s journey over the past few years has been noteworthy, with sales rising from ₹2,396 Cr in FY 2021 to ₹4,045 Cr in FY 2023. However, the latest reporting period for FY 2024 saw a decline in sales to ₹3,163 Cr, which raises questions regarding demand fluctuations and market challenges. The trailing twelve months (TTM) figure stands at ₹4,520 Cr, suggesting a recovery might be underway. The quarterly sales figures also tell a story of volatility; while the March 2024 quarter reported a solid ₹1,312 Cr, subsequent quarters displayed a dip, with sales of ₹785 Cr in June 2024. This inconsistency highlights potential seasonality or operational challenges in maintaining steady growth.
Profitability and Efficiency Metrics
Profitability metrics for Sharda Cropchem reflect both resilience and pressure. The operating profit margin (OPM) stood at 22% in FY 2023, but has since shown signs of strain, declining to 10% in FY 2024. This drop is accompanied by a net profit of ₹304 Cr in FY 2025, down from ₹342 Cr in FY 2023, indicating a potential squeeze on margins. The interest coverage ratio, remarkably high at 311.10x, suggests that the company is comfortably managing its interest obligations, which is a positive signal for investors. However, the return on equity (ROE) fell to 12.17%, down from a more robust 15.32% the previous year, which may raise concerns about the company’s ability to generate returns for shareholders. The cash conversion cycle of 124 days appears manageable, but the efficiency in asset utilization, as indicated by a declining ROCE of 16%, could be an area for improvement.
Balance Sheet Strength and Financial Ratios
Sharda Cropchem’s balance sheet reflects a strong equity base, with reserves reported at ₹2,585 Cr and negligible borrowings of just ₹4 Cr, showcasing a very low debt profile. This financial strength allows the company to operate with a current ratio of 1.81, which indicates a healthy liquidity position, essential for meeting short-term obligations. The price-to-book value ratio stands at 2.06x, suggesting that the stock is valued at a premium compared to its book value, which could indicate market confidence in future growth. However, the operating profit has seen fluctuations, with a notable drop from ₹659 Cr in FY 2023 to ₹303 Cr in FY 2024, raising questions about operational efficiency. The decline in profitability metrics, along with a high dividend payout ratio at 27% in FY 2025, may signal that while the company rewards its shareholders, it could also be limiting reinvestment into business growth.
Shareholding Pattern and Investor Confidence
The shareholding structure of Sharda Cropchem reveals a strong promoter backing at 74.82%, which can be reassuring for investors as it indicates alignment between management and shareholder interests. The foreign institutional investors (FIIs) have gradually increased their stake to 5.26%, reflecting growing confidence in the company’s prospects. Conversely, domestic institutional investors (DIIs) have seen a slight decline in their holdings to 9.26%, which may suggest a mixed sentiment among local investors. The total number of shareholders increased to 67,290, indicating a rising interest in the stock, despite some volatility in its financial performance. This growing shareholder base could provide a buffer against market fluctuations, although the dependency on promoter holding could be a double-edged sword if the business faces challenges.
Outlook, Risks, and Final Insight
Looking ahead, Sharda Cropchem faces a complex landscape. The volatility in revenue and profitability metrics raises concerns about the company’s ability to sustain growth amidst fluctuating market demand. Investors should be cautious of potential risks, including dependence on agricultural cycles and regulatory changes in the agrochemical sector. Additionally, the decline in operating margins could affect future profitability if not addressed. Conversely, the company’s strong balance sheet and low debt levels provide a cushion against economic downturns and operational hiccups. As the company works to stabilize its revenue streams and enhance operational efficiency, investors may find value in its long-term potential, especially if it can leverage its robust market position to navigate these challenges effectively. Balancing these strengths against the risks will be key for investors considering Sharda Cropchem as part of their portfolio.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 6,197 Cr. | 1,436 | 2,114/1,398 | 15.4 | 487 | 0.42 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 787 Cr. | 233 | 391/165 | 16.2 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 62.5 Cr. | 120 | 149/56.6 | 11.2 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,965 Cr. | 229 | 344/224 | 112 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 923 Cr. | 390 | 670/244 | 72.1 | 342 | 0.77 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 10,964.25 Cr | 1,133.75 | 32.22 | 382.34 | 0.44% | 15.21% | 19.87% | 7.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 825 | 722 | 1,017 | 1,482 | 638 | 581 | 632 | 1,312 | 785 | 777 | 929 | 1,829 | 985 |
| Expenses | 772 | 656 | 810 | 1,164 | 697 | 560 | 563 | 1,057 | 708 | 687 | 815 | 1,525 | 770 |
| Operating Profit | 53 | 65 | 207 | 318 | -59 | 21 | 69 | 255 | 77 | 90 | 115 | 303 | 215 |
| OPM % | 6% | 9% | 20% | 21% | -9% | 4% | 11% | 19% | 10% | 12% | 12% | 17% | 22% |
| Other Income | 20 | 10 | 3 | 7 | 26 | 24 | 12 | -2 | 19 | 25 | 1 | 25 | 32 |
| Interest | 1 | 0 | 1 | 2 | 1 | 5 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Depreciation | 55 | 60 | 65 | 68 | 70 | 74 | 69 | 54 | 65 | 69 | 69 | 72 | 78 |
| Profit before tax | 18 | 15 | 143 | 255 | -105 | -34 | 12 | 198 | 31 | 46 | 46 | 256 | 169 |
| Tax % | -28% | 17% | 24% | 22% | -15% | -18% | 62% | 28% | 11% | 7% | 32% | 20% | 16% |
| Net Profit | 23 | 12 | 108 | 199 | -89 | -28 | 5 | 143 | 27 | 42 | 31 | 204 | 143 |
| EPS in Rs | 2.51 | 1.34 | 12.01 | 22.04 | -9.82 | -3.06 | 0.51 | 15.90 | 3.02 | 4.70 | 3.45 | 22.56 | 15.83 |
Last Updated: August 1, 2025, 12:05 pm
Below is a detailed analysis of the quarterly data for Sharda Cropchem Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 985.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,829.00 Cr. (Mar 2025) to 985.00 Cr., marking a decrease of 844.00 Cr..
- For Expenses, as of Jun 2025, the value is 770.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,525.00 Cr. (Mar 2025) to 770.00 Cr., marking a decrease of 755.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 215.00 Cr.. The value appears to be declining and may need further review. It has decreased from 303.00 Cr. (Mar 2025) to 215.00 Cr., marking a decrease of 88.00 Cr..
- For OPM %, as of Jun 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 22.00%, marking an increase of 5.00%.
- For Other Income, as of Jun 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 7.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 78.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 72.00 Cr. (Mar 2025) to 78.00 Cr., marking an increase of 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 169.00 Cr.. The value appears to be declining and may need further review. It has decreased from 256.00 Cr. (Mar 2025) to 169.00 Cr., marking a decrease of 87.00 Cr..
- For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be improving (decreasing) as expected. It has decreased from 20.00% (Mar 2025) to 16.00%, marking a decrease of 4.00%.
- For Net Profit, as of Jun 2025, the value is 143.00 Cr.. The value appears to be declining and may need further review. It has decreased from 204.00 Cr. (Mar 2025) to 143.00 Cr., marking a decrease of 61.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 15.83. The value appears to be declining and may need further review. It has decreased from 22.56 (Mar 2025) to 15.83, marking a decrease of 6.73.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 790 | 1,061 | 1,222 | 1,399 | 1,707 | 1,998 | 2,003 | 2,396 | 3,580 | 4,045 | 3,163 | 4,320 | 4,672 |
| Expenses | 630 | 878 | 941 | 1,075 | 1,343 | 1,621 | 1,653 | 1,945 | 2,884 | 3,386 | 2,860 | 3,705 | 3,906 |
| Operating Profit | 160 | 183 | 281 | 324 | 364 | 376 | 350 | 450 | 696 | 659 | 303 | 615 | 766 |
| OPM % | 20% | 17% | 23% | 23% | 21% | 19% | 17% | 19% | 19% | 16% | 10% | 14% | 16% |
| Other Income | 32 | 25 | 23 | 14 | 9 | -22 | -12 | 46 | 29 | 40 | 60 | 60 | 88 |
| Interest | 8 | 9 | 8 | 9 | 15 | 20 | 16 | 16 | 15 | 20 | 24 | 21 | 2 |
| Depreciation | 29 | 23 | 35 | 56 | 70 | 99 | 137 | 170 | 245 | 248 | 267 | 275 | 295 |
| Profit before tax | 155 | 175 | 261 | 272 | 287 | 235 | 185 | 309 | 464 | 431 | 72 | 378 | 557 |
| Tax % | 29% | 30% | 33% | 30% | 34% | 25% | 11% | 26% | 25% | 21% | 56% | 20% | |
| Net Profit | 111 | 123 | 175 | 190 | 191 | 176 | 165 | 229 | 349 | 342 | 32 | 304 | 452 |
| EPS in Rs | 12.31 | 13.63 | 19.41 | 21.11 | 21.14 | 19.55 | 18.25 | 25.40 | 38.71 | 37.90 | 3.53 | 33.74 | 50.08 |
| Dividend Payout % | 16% | 18% | 21% | 19% | 19% | 20% | 22% | 20% | 16% | 16% | 85% | 27% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 10.81% | 42.28% | 8.57% | 0.53% | -7.85% | -6.25% | 38.79% | 52.40% | -2.01% | -90.64% | 850.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 31.47% | -33.70% | -8.05% | -8.38% | 1.60% | 45.04% | 13.61% | -54.41% | -88.64% | 940.64% |
Sharda Cropchem Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 17% |
| 3 Years: | 6% |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | -5% |
| TTM: | 184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 27% |
| 3 Years: | 21% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: December 4, 2025, 1:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 |
| Reserves | 466 | 564 | 715 | 870 | 1,045 | 1,194 | 1,313 | 1,524 | 1,822 | 2,142 | 2,147 | 2,410 | 2,585 |
| Borrowings | 40 | 38 | 2 | 0 | 170 | 0 | 0 | 81 | 47 | 3 | 18 | 8 | 4 |
| Other Liabilities | 319 | 354 | 522 | 686 | 914 | 914 | 940 | 1,163 | 1,779 | 2,108 | 1,773 | 2,205 | 2,224 |
| Total Liabilities | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 4,903 |
| Fixed Assets | 64 | 88 | 130 | 210 | 226 | 372 | 416 | 544 | 592 | 668 | 708 | 750 | 1,109 |
| CWIP | 133 | 149 | 210 | 232 | 360 | 220 | 161 | 131 | 212 | 204 | 283 | 291 | 0 |
| Investments | 174 | 95 | 90 | 61 | 22 | 212 | 116 | 83 | 134 | 32 | 159 | 294 | 555 |
| Other Assets | 542 | 715 | 899 | 1,143 | 1,611 | 1,394 | 1,650 | 2,099 | 2,800 | 3,439 | 2,878 | 3,377 | 3,240 |
| Total Assets | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 4,903 |
Below is a detailed analysis of the balance sheet data for Sharda Cropchem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 90.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 90.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,585.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,410.00 Cr. (Mar 2025) to 2,585.00 Cr., marking an increase of 175.00 Cr..
- For Borrowings, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,224.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,205.00 Cr. (Mar 2025) to 2,224.00 Cr., marking an increase of 19.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,903.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,713.00 Cr. (Mar 2025) to 4,903.00 Cr., marking an increase of 190.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,109.00 Cr.. The value appears strong and on an upward trend. It has increased from 750.00 Cr. (Mar 2025) to 1,109.00 Cr., marking an increase of 359.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 291.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 291.00 Cr..
- For Investments, as of Sep 2025, the value is 555.00 Cr.. The value appears strong and on an upward trend. It has increased from 294.00 Cr. (Mar 2025) to 555.00 Cr., marking an increase of 261.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,240.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,377.00 Cr. (Mar 2025) to 3,240.00 Cr., marking a decrease of 137.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,903.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,713.00 Cr. (Mar 2025) to 4,903.00 Cr., marking an increase of 190.00 Cr..
Notably, the Reserves (2,585.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 120.00 | 145.00 | 279.00 | 324.00 | 194.00 | 376.00 | 350.00 | 369.00 | 649.00 | 656.00 | 285.00 | 607.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 185 | 156 | 185 | 175 | 191 | 148 | 180 | 177 | 157 | 165 | 173 | 165 |
| Inventory Days | 57 | 72 | 74 | 117 | 169 | 96 | 100 | 117 | 130 | 145 | 155 | 117 |
| Days Payable | 146 | 117 | 179 | 186 | 202 | 167 | 180 | 180 | 172 | 176 | 144 | 158 |
| Cash Conversion Cycle | 97 | 111 | 81 | 106 | 158 | 77 | 100 | 114 | 115 | 134 | 184 | 124 |
| Working Capital Days | 67 | 82 | 95 | 99 | 94 | 71 | 101 | 94 | 88 | 97 | 128 | 92 |
| ROCE % | 28% | 27% | 36% | 32% | 27% | 23% | 18% | 21% | 26% | 21% | 4% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 5,406,610 | 1.23 | 466.4 | N/A | N/A | N/A |
| DSP Small Cap Fund | 1,750,000 | 0.89 | 150.96 | 3,587,791 | 2025-12-07 00:37:56 | -51.22% |
| HDFC Hybrid Equity Fund | 920,000 | 0.32 | 79.36 | 846,062 | 2025-12-15 00:39:12 | 8.74% |
| Bandhan Balanced Advantage Fund | 50,000 | 0.19 | 4.31 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| Diluted EPS (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| Cash EPS (Rs.) | 64.19 | 33.15 | 65.41 | 65.91 | 44.30 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 277.16 | 248.00 | 247.44 | 212.01 | 178.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 277.16 | 248.00 | 247.44 | 212.01 | 178.96 |
| Revenue From Operations / Share (Rs.) | 478.81 | 350.59 | 448.36 | 396.78 | 265.53 |
| PBDIT / Share (Rs.) | 72.61 | 37.98 | 75.74 | 78.89 | 53.50 |
| PBIT / Share (Rs.) | 42.17 | 8.37 | 48.24 | 51.70 | 34.61 |
| PBT / Share (Rs.) | 41.93 | 7.97 | 47.74 | 51.46 | 34.30 |
| Net Profit / Share (Rs.) | 33.74 | 3.54 | 37.91 | 38.71 | 25.41 |
| NP After MI And SOA / Share (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| PBDIT Margin (%) | 15.16 | 10.83 | 16.89 | 19.88 | 20.14 |
| PBIT Margin (%) | 8.80 | 2.38 | 10.75 | 13.03 | 13.03 |
| PBT Margin (%) | 8.75 | 2.27 | 10.64 | 12.96 | 12.91 |
| Net Profit Margin (%) | 7.04 | 1.00 | 8.45 | 9.75 | 9.56 |
| NP After MI And SOA Margin (%) | 7.04 | 1.00 | 8.45 | 9.75 | 9.56 |
| Return on Networth / Equity (%) | 12.17 | 1.42 | 15.32 | 18.26 | 14.19 |
| Return on Capital Employeed (%) | 13.88 | 3.07 | 18.28 | 22.73 | 18.10 |
| Return On Assets (%) | 6.44 | 0.78 | 7.85 | 9.33 | 8.00 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
| Asset Turnover Ratio (%) | 0.98 | 0.75 | 0.85 | 0.93 | 0.80 |
| Current Ratio (X) | 1.81 | 1.86 | 1.65 | 1.69 | 1.84 |
| Quick Ratio (X) | 1.32 | 1.23 | 1.08 | 1.16 | 1.38 |
| Inventory Turnover Ratio (X) | 4.40 | 1.40 | 1.59 | 1.96 | 2.19 |
| Dividend Payout Ratio (NP) (%) | 18.16 | 85.75 | 16.21 | 15.49 | 7.87 |
| Dividend Payout Ratio (CP) (%) | 9.54 | 9.14 | 9.39 | 9.10 | 4.51 |
| Earning Retention Ratio (%) | 81.84 | 14.25 | 83.79 | 84.51 | 92.13 |
| Cash Earning Retention Ratio (%) | 90.46 | 90.86 | 90.61 | 90.90 | 95.49 |
| Interest Coverage Ratio (X) | 311.10 | 94.68 | 151.52 | 321.65 | 174.12 |
| Interest Coverage Ratio (Post Tax) (X) | 145.56 | 9.82 | 76.83 | 158.84 | 83.69 |
| Enterprise Value (Cr.) | 4929.40 | 2811.46 | 4234.14 | 5420.45 | 2398.75 |
| EV / Net Operating Revenue (X) | 1.14 | 0.88 | 1.05 | 1.51 | 1.00 |
| EV / EBITDA (X) | 7.52 | 8.21 | 6.20 | 7.62 | 4.97 |
| MarketCap / Net Operating Revenue (X) | 1.19 | 0.91 | 1.09 | 1.55 | 1.08 |
| Retention Ratios (%) | 81.83 | 14.24 | 83.78 | 84.50 | 92.12 |
| Price / BV (X) | 2.06 | 1.29 | 1.98 | 2.90 | 1.61 |
| Price / Net Operating Revenue (X) | 1.19 | 0.91 | 1.09 | 1.55 | 1.08 |
| EarningsYield | 0.05 | 0.01 | 0.07 | 0.06 | 0.08 |
After reviewing the key financial ratios for Sharda Cropchem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 64.19. This value is within the healthy range. It has increased from 33.15 (Mar 24) to 64.19, marking an increase of 31.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 277.16. It has increased from 248.00 (Mar 24) to 277.16, marking an increase of 29.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 277.16. It has increased from 248.00 (Mar 24) to 277.16, marking an increase of 29.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 478.81. It has increased from 350.59 (Mar 24) to 478.81, marking an increase of 128.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 72.61. This value is within the healthy range. It has increased from 37.98 (Mar 24) to 72.61, marking an increase of 34.63.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.17. This value is within the healthy range. It has increased from 8.37 (Mar 24) to 42.17, marking an increase of 33.80.
- For PBT / Share (Rs.), as of Mar 25, the value is 41.93. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 41.93, marking an increase of 33.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.54 (Mar 24) to 33.74, marking an increase of 30.20.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For PBDIT Margin (%), as of Mar 25, the value is 15.16. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 15.16, marking an increase of 4.33.
- For PBIT Margin (%), as of Mar 25, the value is 8.80. This value is below the healthy minimum of 10. It has increased from 2.38 (Mar 24) to 8.80, marking an increase of 6.42.
- For PBT Margin (%), as of Mar 25, the value is 8.75. This value is below the healthy minimum of 10. It has increased from 2.27 (Mar 24) to 8.75, marking an increase of 6.48.
- For Net Profit Margin (%), as of Mar 25, the value is 7.04. This value is within the healthy range. It has increased from 1.00 (Mar 24) to 7.04, marking an increase of 6.04.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.04. This value is below the healthy minimum of 8. It has increased from 1.00 (Mar 24) to 7.04, marking an increase of 6.04.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.17. This value is below the healthy minimum of 15. It has increased from 1.42 (Mar 24) to 12.17, marking an increase of 10.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.88. This value is within the healthy range. It has increased from 3.07 (Mar 24) to 13.88, marking an increase of 10.81.
- For Return On Assets (%), as of Mar 25, the value is 6.44. This value is within the healthy range. It has increased from 0.78 (Mar 24) to 6.44, marking an increase of 5.66.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.98. It has increased from 0.75 (Mar 24) to 0.98, marking an increase of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.81, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.32. This value is within the healthy range. It has increased from 1.23 (Mar 24) to 1.32, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 4.40, marking an increase of 3.00.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.16. This value is below the healthy minimum of 20. It has decreased from 85.75 (Mar 24) to 18.16, marking a decrease of 67.59.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 9.54. This value is below the healthy minimum of 20. It has increased from 9.14 (Mar 24) to 9.54, marking an increase of 0.40.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.84. This value exceeds the healthy maximum of 70. It has increased from 14.25 (Mar 24) to 81.84, marking an increase of 67.59.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 90.46. This value exceeds the healthy maximum of 70. It has decreased from 90.86 (Mar 24) to 90.46, marking a decrease of 0.40.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 311.10. This value is within the healthy range. It has increased from 94.68 (Mar 24) to 311.10, marking an increase of 216.42.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 145.56. This value is within the healthy range. It has increased from 9.82 (Mar 24) to 145.56, marking an increase of 135.74.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,929.40. It has increased from 2,811.46 (Mar 24) to 4,929.40, marking an increase of 2,117.94.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.14. This value is within the healthy range. It has increased from 0.88 (Mar 24) to 1.14, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 7.52. This value is within the healthy range. It has decreased from 8.21 (Mar 24) to 7.52, marking a decrease of 0.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.19. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.19, marking an increase of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 81.83. This value exceeds the healthy maximum of 70. It has increased from 14.24 (Mar 24) to 81.83, marking an increase of 67.59.
- For Price / BV (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 2.06, marking an increase of 0.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.19. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.19, marking an increase of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sharda Cropchem Ltd:
- Net Profit Margin: 7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.88% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.17% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 145.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.32
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.7 (Industry average Stock P/E: 32.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Prime Business Park, Dashrathlal Joshi Road, Mumbai Maharashtra 400056 | co.sec@shardaintl.com http://www.shardacropchem.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramprakash V Bubna | Chairman & Managing Director |
| Mrs. Sharda R Bubna | Whole Time Director |
| Mr. Ashish R Bubna | Whole Time Director |
| Mr. Manish R Bubna | Whole Time Director |
| Ms. Sonal Desai | Independent Director |
| Mr. H S Upendra Kamath | Independent Director |
| Mr. Vinod Kathuria | Independent Director |
| Mr. Shalin Divatia | Independent Director |
FAQ
What is the intrinsic value of Sharda Cropchem Ltd?
Sharda Cropchem Ltd's intrinsic value (as of 16 December 2025) is 565.21 which is 39.55% lower the current market price of 935.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 8,437 Cr. market cap, FY2025-2026 high/low of 1,181/440, reserves of ₹2,585 Cr, and liabilities of 4,903 Cr.
What is the Market Cap of Sharda Cropchem Ltd?
The Market Cap of Sharda Cropchem Ltd is 8,437 Cr..
What is the current Stock Price of Sharda Cropchem Ltd as on 16 December 2025?
The current stock price of Sharda Cropchem Ltd as on 16 December 2025 is 935.
What is the High / Low of Sharda Cropchem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sharda Cropchem Ltd stocks is 1,181/440.
What is the Stock P/E of Sharda Cropchem Ltd?
The Stock P/E of Sharda Cropchem Ltd is 18.7.
What is the Book Value of Sharda Cropchem Ltd?
The Book Value of Sharda Cropchem Ltd is 297.
What is the Dividend Yield of Sharda Cropchem Ltd?
The Dividend Yield of Sharda Cropchem Ltd is 0.96 %.
What is the ROCE of Sharda Cropchem Ltd?
The ROCE of Sharda Cropchem Ltd is 16.5 %.
What is the ROE of Sharda Cropchem Ltd?
The ROE of Sharda Cropchem Ltd is 12.6 %.
What is the Face Value of Sharda Cropchem Ltd?
The Face Value of Sharda Cropchem Ltd is 10.0.